Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Shares Acquired by Barclays PLC

Barclays PLC raised its stake in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 326.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 29,959 shares of the company’s stock after acquiring an additional 22,941 shares during the quarter. Barclays PLC’s holdings in Telomir Pharmaceuticals were worth $123,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Wells Fargo & Company MN increased its stake in Telomir Pharmaceuticals by 458.3% during the 4th quarter. Wells Fargo & Company MN now owns 10,044 shares of the company’s stock worth $41,000 after buying an additional 8,245 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Telomir Pharmaceuticals by 73.3% during the fourth quarter. Geode Capital Management LLC now owns 413,677 shares of the company’s stock worth $1,705,000 after purchasing an additional 174,940 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Telomir Pharmaceuticals by 1,096.4% in the 4th quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company’s stock valued at $171,000 after purchasing an additional 37,980 shares during the last quarter. Corebridge Financial Inc. lifted its holdings in Telomir Pharmaceuticals by 273.8% in the 4th quarter. Corebridge Financial Inc. now owns 9,613 shares of the company’s stock valued at $40,000 after purchasing an additional 7,041 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Telomir Pharmaceuticals during the 4th quarter worth $62,000.

Analysts Set New Price Targets

Several equities research analysts recently commented on TELO shares. Rodman & Renshaw began coverage on Telomir Pharmaceuticals in a report on Friday, February 21st. They issued a “buy” rating and a $15.00 price target for the company. RODMAN&RENSHAW upgraded shares of Telomir Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 20th.

Telomir Pharmaceuticals Trading Down 3.3%

TELO stock opened at $2.66 on Thursday. Telomir Pharmaceuticals, Inc. has a twelve month low of $2.35 and a twelve month high of $8.40. The stock has a market cap of $79.17 million, a P/E ratio of -4.59 and a beta of 0.17. The company’s 50 day moving average is $3.16 and its two-hundred day moving average is $4.04.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. On average, equities research analysts predict that Telomir Pharmaceuticals, Inc. will post -0.4 earnings per share for the current year.

Telomir Pharmaceuticals Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.